[go: up one dir, main page]

DK369287D0 - Immunotoksiner og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende dem - Google Patents

Immunotoksiner og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende dem

Info

Publication number
DK369287D0
DK369287D0 DK369287A DK369287A DK369287D0 DK 369287 D0 DK369287 D0 DK 369287D0 DK 369287 A DK369287 A DK 369287A DK 369287 A DK369287 A DK 369287A DK 369287 D0 DK369287 D0 DK 369287D0
Authority
DK
Denmark
Prior art keywords
immunotoxines
procedures
preparing
pharmaceutical agents
agents containing
Prior art date
Application number
DK369287A
Other languages
English (en)
Other versions
DK369287A (da
Inventor
Luigi Barbieri
Pierre Casellas
Fiorenzo Stirpe
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DK369287D0 publication Critical patent/DK369287D0/da
Publication of DK369287A publication Critical patent/DK369287A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6821—Plant heterodimeric toxins, e.g. abrin or modeccin
    • A61K47/6823—Double chain ricin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK369287A 1986-07-15 1987-07-15 Immunotoksiner og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende dem DK369287A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8610297A FR2601679B1 (fr) 1986-07-15 1986-07-15 Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant

Publications (2)

Publication Number Publication Date
DK369287D0 true DK369287D0 (da) 1987-07-15
DK369287A DK369287A (da) 1988-01-16

Family

ID=9337440

Family Applications (1)

Application Number Title Priority Date Filing Date
DK369287A DK369287A (da) 1986-07-15 1987-07-15 Immunotoksiner og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende dem

Country Status (15)

Country Link
US (1) US4981953A (da)
EP (1) EP0255424B1 (da)
JP (1) JPS63146831A (da)
KR (1) KR880001299A (da)
AT (1) ATE67507T1 (da)
AU (1) AU614263B2 (da)
DE (1) DE3773077D1 (da)
DK (1) DK369287A (da)
ES (1) ES2040269T3 (da)
FR (1) FR2601679B1 (da)
GR (1) GR3003097T3 (da)
IL (1) IL83183A (da)
NZ (1) NZ221065A (da)
PT (1) PT85317B (da)
ZA (1) ZA875176B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635384A (en) * 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
US5248606A (en) * 1990-06-11 1993-09-28 Dowelanco Dna encoding inactive precursor and active forms of maize ribosome inactivating protein
US5191066A (en) * 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
DE4310142A1 (de) * 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Immunologisch aktive Konjugate und ein Verfahren zu ihrer Herstellung
CA2331789C (en) 1998-07-13 2013-09-10 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
HK1045700B (zh) 1999-04-28 2007-07-27 德克萨斯大学董事会 用於通过选择性抑制vegf来治疗癌症的组合物和方法
EP1188446B1 (en) * 2000-09-15 2009-08-05 Institut Pasteur Proteinaceous vectors for molecule delivery to CD11b expressing cells
KR100512870B1 (ko) * 2002-10-15 2005-09-07 주식회사 엔지켐 7α-메톡시세팔로스포린 유도체 나트륨염 7수화물의제조방법
CN105594121B (zh) 2013-07-09 2019-06-14 天工方案公司 带有输入功率保护电路的功率放大器

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
PT80662B (en) * 1984-06-20 1986-12-09 Sanofi Sa Process to obtain anti-tumoral glycoprotein modified on its glycidic portions
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4744981A (en) * 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates

Also Published As

Publication number Publication date
DE3773077D1 (de) 1991-10-24
US4981953A (en) 1991-01-01
PT85317A (fr) 1987-08-01
IL83183A (en) 1992-05-25
ES2040269T3 (es) 1993-10-16
IL83183A0 (en) 1987-12-31
FR2601679A1 (fr) 1988-01-22
JPS63146831A (ja) 1988-06-18
AU7556487A (en) 1988-01-21
PT85317B (pt) 1990-04-30
DK369287A (da) 1988-01-16
EP0255424A1 (fr) 1988-02-03
AU614263B2 (en) 1991-08-29
KR880001299A (ko) 1988-04-22
EP0255424B1 (fr) 1991-09-18
NZ221065A (en) 1990-06-26
FR2601679B1 (fr) 1990-05-25
ATE67507T1 (de) 1991-10-15
GR3003097T3 (en) 1993-02-17
ZA875176B (en) 1988-03-30

Similar Documents

Publication Publication Date Title
DK121683D0 (da) Fremgangsmade til fremstilling af immunoenzymatiske konjugater
KR860004923A (ko) 폴리삭카라이드-단백질 결합체, 이의 제조방법 및 이를 함유하는 조성물
DK369287D0 (da) Immunotoksiner og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende dem
NO830110L (no) 6-substituert-s-triazolo(3,4-a)ftalazinderivater og fremgangsmaate for deres fremstilling
ES2098140T3 (es) Liosferas que contienen gonadotropina.
NL7903871A (nl) Werkwijze ter bereiding van een prostacycline bevattend farmaceutisch preparaat, alsmede als zodanig verkregen preparaten.
ATE185150T1 (de) Proteinkomplex
NO173336C (no) Fremgangsm}te til isolering av basalmembranproteiner fra human- eller animalvev og anvendelse av det oppn}dde protein
SE8404334D0 (sv) 16-fluoro-16,17-didehydro-prostanoids and process for their preparation
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
PT90296A (pt) Processo para a preparacao de anticorpos monoclonais contra pseudomonas aeruginosa e de composicoes farmaceuticas que os contem
SE8503447D0 (sv) Farmaceutiska och kosmetiska kompositioner, innehallande dihydroxi-1,8-fenyl-10-antron-9 som verksam bestandsdel, samt sett att framstella den verksamma foreningen
ES2053704T3 (es) Un metodo de estabilizacion de una composicion acuosa consistente en uno o mas anticuerpos monoclonales.
DE69008859D1 (de) Modifizierte menschliche anti-rh(d)-antikörper.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment